Syndax Pharmaceuticals (SNDX) recently reported encouraging Phase 1/2 data for its Revuforj combination regimen in relapsed or refractory acute myeloid leukemia, with high response and remission rates across genetic subgroups attracting fresh investor attention.

Syndax Pharmaceuticals' US$21.82 share price has moved sharply around recent news, with a 1 month share price return of 21.09% but a 3 month share price decline of 13.24%, while the 1 year total shareholder return of 142.44% highlights how strongly the stock has reacted to the oncology data and renewed interest.

If the Revuforj results have you looking more closely at cancer and biotech opportunities, it could be a good moment to broaden your watchlist with 40 healthcare AI stocks

With Syndax Pharmaceuticals trading at US$21.82 and sitting well below some analyst price targets despite strong Revuforj headlines, it raises a key question: is this an overlooked cancer stock, or is the market already incorporating expectations about its future growth?

Most Popular Narrative: 44.8% Undervalued

Compared with the last close at $21.82, the most widely followed narrative for Syndax Pharmaceuticals points to a fair value of $39.50, framing the current oncology excitement inside a much larger earnings and cash flow story.

Fixed operating expense base, together with expanding product sales and cash flow contributions from both franchises, is positioned to drive significant operating leverage, boosting net margins and accelerating the pathway to profitability. Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for targeted therapies, supporting sustained multi-year earnings momentum.

Want to see what sits underneath that optimism for Syndax Pharmaceuticals, including the revenue curve, margin shift, and earnings profile that support a near $40 fair value? The narrative leans on a tight set of assumptions around future sales scale, profitability and the price that investors might be willing to pay for those earnings.

Result: Fair Value of $39.50 (UNDERVALUED)

However, the Syndax Pharmaceuticals story can change quickly if key trials disappoint or if Revuforj and Niktimvo adoption falls short of analyst expectations.

Next Steps

If this upbeat tone around Syndax Pharmaceuticals has you curious, do not wait for consensus to settle before checking the data yourself and weighing the 2 key rewards

Looking for more investment ideas beyond Syndax Pharmaceuticals?

If you like what you see with Syndax Pharmaceuticals, do not stop there. Broaden your opportunity set now so you are not relying on a single story.

• Target potential mispricing by scanning for quality stocks trading below their estimated worth using the 44 high quality undervalued stocks.
• Strengthen your income stream by hunting for companies with higher yields and consistent payouts through the 7 dividend fortresses.
• Reduce portfolio stress by focusing on companies with sturdier finances and cleaner balance sheets using the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.